Sandborn William J
Division of Gastroenterology and Hepatology, 200 First Street SW, Mayo Clinic, Rochester, MN 55905, USA.
J Clin Gastroenterol. 2008 Apr;42(4):338-44. doi: 10.1097/MCG.0b013e3181595b56.
5-aminosalicylic acid (5-ASA) is the standard first-line treatment for mild-to-moderate ulcerative colitis. A variety of 5-ASA delivery systems are available and in development, including both oral and rectal formulations; all of which aim to deliver the active drug to the colon while minimizing systemic absorption. Because the efficacy of most oral 5-ASA therapies is broadly similar, the appropriate selection of a given formulation often relies on other factors. This article explores the differences between oral 5-ASA formulations in terms of their delivery system, reviews the available data on oral 5-ASA treatment efficacy and tolerability, and examines the rationale for changing from one 5-ASA formulation to another if a patient does not respond to, or worsens on, their existing agent.
5-氨基水杨酸（5-ASA）是轻至中度溃疡性结肠炎的标准一线治疗药物。多种5-ASA给药系统可供使用且仍在研发中，包括口服和直肠制剂；所有这些制剂的目的都是将活性药物输送到结肠，同时尽量减少全身吸收。由于大多数口服5-ASA疗法的疗效大致相似，因此特定制剂的适当选择通常取决于其他因素。本文探讨了口服5-ASA制剂在给药系统方面的差异，回顾了口服5-ASA治疗疗效和耐受性的现有数据，并研究了如果患者对现有药物无反应或病情恶化，从一种5-ASA制剂更换为另一种制剂的基本原理。
